Published in Clin Infect Dis on August 16, 2004
Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain | NCT03699020
Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr (2012) 1.27
Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage (2011) 1.23
Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med (2010) 1.07
Prescription long-term opioid use in HIV-infected patients. Clin J Pain (2012) 1.05
Patient and provider-reported symptoms in the post-cART era. AIDS Behav (2011) 1.01
Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr (2014) 1.00
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDS (2012) 1.00
Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy. J Pain Symptom Manage (2009) 0.94
Pain and symptom control in HIV disease: under-researched and poorly managed. Clin Infect Dis (2005) 0.93
Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol (2006) 0.93
Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). Oral Dis (2008) 0.92
Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. J Neurovirol (2010) 0.91
Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients. AIDS Patient Care STDS (2014) 0.86
HIV or HIV-therapy? Causal attributions of symptoms and their impact on treatment decisions among women and men with HIV. Eur J Med Res (2009) 0.81
Hormonal contraception and HIV-positive women: metabolic concerns and management strategies. J Midwifery Womens Health (2008) 0.78
Pain self-management in HIV-infected individuals with chronic pain: a qualitative study. Pain Med (2015) 0.77
Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients. Clin J Pain (2014) 0.77
HIV protease inhibitors in gut barrier dysfunction and liver injury. Curr Opin Pharmacol (2014) 0.77
Fall frequency and associated factors among men and women with or at risk for HIV infection. HIV Med (2016) 0.76
Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic. Pain Med (2013) 0.75
Sleep Apnea Symptoms as a Predictor of Fatigue in an Urban HIV Clinic. AIDS Patient Care STDS (2015) 0.75
HIV-related symptoms and patient clusters among Chileans living with HIV. AIDS Care (2012) 0.75
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med (2002) 5.52
Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry (2001) 5.22
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry (1993) 2.77
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med (2003) 2.64
Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr (2002) 2.30
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials (2001) 1.71
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav (2003) 1.25
Experience and covariates of depressive symptoms among a cohort of HIV infected women. Soc Work Health Care (2001) 1.14
Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med (2000) 1.12
Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS (2000) 1.11
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr (2000) 1.11
Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand (2002) 1.09
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS (2002) 1.07
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS (2001) 1.01
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med (2014) 3.66
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis (2010) 3.26
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis (2006) 2.91
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med (2006) 2.67
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Measuring retention in HIV care: the elusive gold standard. J Acquir Immune Defic Syndr (2012) 2.47
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Driving status and risk of entry into long-term care in older adults. Am J Public Health (2006) 2.32
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis (2012) 2.16
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis (2008) 1.99
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr (2011) 1.98
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis (2004) 1.89
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep (2011) 1.65
T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis (2011) 1.64
Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction (2011) 1.64
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses (2007) 1.61
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS (2006) 1.55
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS (2007) 1.53
Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause (2015) 1.49
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS (2010) 1.46
The effect of neighborhood deprivation and residential relocation on long-term injection cessation among injection drug users (IDUs) in Baltimore, Maryland. Addiction (2011) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS (2013) 1.43
Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health (2009) 1.43
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis (2012) 1.42
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (2010) 1.37
Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr (2012) 1.37
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS (2009) 1.36
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
Virologic and immunologic response to HAART, by age and regimen class. AIDS (2010) 1.34
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis (2003) 1.33
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis (2004) 1.33
The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction (2005) 1.32
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32